What did @radiantbeauty1986 actually say?
She quit Zepbound after a single injection, citing "tiredness and all the other things" she started feeling after her first 15 mg dose. Her plan going forward is to focus on diet and start exercising, which she admits she "should have been doing in the first place."
To be fair, she is not making medical claims here. She is sharing a personal decision. But 84,700 people watched this, and some of them are probably on tirzepatide or considering it. That means her framing of side effects as a reason to quit cold turkey after one shot carries real weight, whether she intended it to or not. Her experience is valid. The implicit message that one bad week means the medication is not worth continuing deserves more scrutiny.
Does the science back this up?
The fatigue and other side effects she experienced after her first injection are well-documented and expected, not a sign the drug is wrong for her. The problem is she experienced them at the highest available dose, which is not how tirzepatide is supposed to be started.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) used a dose-escalation protocol starting at 2.5 mg weekly for four weeks before increasing. Side effects in that trial were most common during escalation periods, and most were transient. Fatigue specifically is listed as a known adverse effect, appearing in roughly 10 to 14 percent of participants across dose levels. Importantly, discontinuation rates due to side effects in SURMOUNT-1 were around 4 to 7 percent, meaning the overwhelming majority of people who experienced early symptoms stayed on the drug and saw significant weight loss outcomes averaging 20.9 percent of body weight at 72 weeks on the 15 mg dose.
Starting at 15 mg is not standard initiation. If that is what happened, it matters enormously to how we interpret her reaction.
What did they get wrong (or right)?
She got her own experience right. Tiredness after a tirzepatide injection is real and common, especially at higher doses. Credit where it is due. But the framing around "15 milligrams" as a first shot is where things get complicated and potentially misleading for viewers.
Eli Lilly's prescribing information for Zepbound specifies a starting dose of 2.5 mg weekly, titrating upward every four weeks. The 15 mg dose is the maximum maintenance dose, not a starting point. If she genuinely received 15 mg as her first injection, that would be an unusual prescribing decision that warrants a conversation with her provider, not a reason to abandon the medication entirely. It is also possible she misspoke and meant 2.5 mg, or confused dose increments. Either way, the video does not clarify this, and viewers may walk away thinking standard Zepbound starter doses produce debilitating fatigue, which is not what the clinical data shows.
Her pivot to diet and exercise is not wrong. Those interventions have solid evidence. But presenting them as an either/or alternative to GLP-1 therapy misses the clinical picture. GLP-1 medications work alongside lifestyle changes, not instead of them.
What should you actually know?
Early side effects on tirzepatide are common, manageable, and usually temporary. Stopping after one injection does not give the drug a fair trial, and it does not reflect how clinical protocols are designed.
A few things worth knowing if you are considering or currently on Zepbound. First, standard initiation starts at 2.5 mg weekly, not 15 mg. The dose escalation schedule exists specifically to reduce gastrointestinal and systemic side effects. Second, fatigue, nausea, and reduced appetite are pharmacologically expected responses to GLP-1 and GIP receptor activation, not signs of an adverse reaction in most cases. Third, if side effects feel unmanageable, the right move is contacting your prescriber, not quitting unilaterally. Dose adjustments, injection timing changes, and dietary modifications during titration can significantly reduce symptom burden. Fourth, the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that discontinuing tirzepatide after weight loss leads to substantial weight regain, reinforcing that the decision to stop is not trivial and should involve a clinical conversation. This video, while honest about one person's frustration, is not a substitute for that conversation.